Overall | Group_A | Group_B | P | |
---|---|---|---|---|
Cases | 234 | 112 | 122 | |
pT_stage (%) | 0.809 | |||
pT2b | 16 (6.8) | 8 (7.1) | 8 (6.6) | |
pT2c | 125 (53.4) | 63 (56.2) | 62 (50.8) | |
pT3a | 56 (23.9) | 24 (21.4) | 32 (26.2) | |
pT3b | 37 (15.8) | 17 (15.2) | 20 (16.4) | |
Patho_GS (%) | 0.638 | |||
3 + 3 | 16 (6.8) | 7 (6.2) | 9 (7.4) | |
3 + 4 | 70 (29.9) | 27 (24.1) | 43 (35.2) | |
4 + 3 | 100 (42.7) | 57 (50.9) | 43 (35.2) | |
4 + 4 | 3 (1.3) | 1 (0.9) | 2 (1.6) | |
4 + 5 | 30 (12.8) | 12 (10.7) | 18 (14.8) | |
5 + 3 | 7 (3.0) | 3 (2.7) | 4 (3.3) | |
5 + 4 | 8 (3.4) | 5 (4.5) | 3 (2.5) | |
SurgicalMargin (%) | 1 | |||
Negative | 159 (67.9) | 76 (67.9) | 83 (68.0) | |
Postive | 75 (32.1) | 36 (32.1) | 39 (32.0) | |
BioChemicalRecurrence (%) | 1 | |||
Negative | 209 (89.3) | 100 (89.3) | 109 (89.3) | |
Positive | 25 (10.7) | 12 (10.7) | 13 (10.7) | |
Continence (%) | ||||
Third month | 186 (79.5) | 92 (82.1) | 94 (77.0) | 0.423 |
Sixth month | 196 (83.8) | 97 (86.6) | 99 (81.1) | 0.340 |
Twelfth month | 206 (88.0) | 102 (91.1) | 104 (85.2) | 0.242 |